协调照护优化2型糖尿病心血管预防治疗:一项随机临床试验
该集群随机临床试验纳入43家美国心脏病学门诊的1049名2型糖尿病合并动脉粥样硬化性心血管疾病成人,评估协调多方面干预(评估、教育、反馈)与常规照护相比对处方全部3类推荐治疗比例的影响。结果显示干预组37.9% vs 常规照护组14.5%在随访时被处方全部3类治疗,差异23.4%(调整OR 4.38,95%CI 2.49-7.71;P<.001),但未显著改变动脉粥样硬化性心血管疾病危险因素。
要点
- 干预组37.9%被处方全部3类推荐治疗,常规照护组14.5%,差异23.4%(调整OR 4.38)。
- 干预组SGLT2抑制剂和/或GLP-1RA处方比例从12.3%升至60.4%,常规照护组从14.5%升至35.5%。
- 干预未显著改变动脉粥样硬化性心血管疾病危险因素,复合次要结局调整HR 0.79(95%CI 0.46-1.33)。
核心结论
- 协调多方面干预增加了2型糖尿病合并动脉粥样硬化性心血管疾病成人中3类循证治疗的处方比例。
研究设计与样本
- 集群随机临床试验,纳入43家美国心脏病学门诊,2019年7月至2022年5月招募参与者,随访至2022年12月。
- 参与者为未全部服用3类循证治疗的2型糖尿病合并动脉粥样硬化性心血管疾病成人,干预组459例,常规照护组590例,共1049例。
主要发现
- 末次随访时干预组173/457(37.9%)被处方全部3类治疗,常规照护组85/588(14.5%),差异23.4%(调整OR 4.38,95%CI 2.49-7.71;P<.001)。
- 高强度他汀处方率干预组从66.5%升至70.7%,常规照护组从58.2%降至56.8%(调整OR 1.73,95%CI 1.06-2.83)。
- ACEI或ARB处方率干预组从75.1%升至81.4%,常规照护组从69.6%降至68.4%(调整OR 1.82,95%CI 1.14-2.91)。
- SGLT2抑制剂和/或GLP-1RA处方率干预组从12.3%升至60.4%,常规照护组从14.5%升至35.5%(调整OR 3.11,95%CI 2.08-4.64)。
- 干预未伴随动脉粥样硬化性心血管疾病危险因素的变化;复合次要结局干预组23/457(5%)vs 常规照护组40/588(6.8%),调整HR 0.79(95%CI 0.46-1.33)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, education, and feedback vs usual care on the proportion of adults with type 2 diabetes and atherosclerotic cardiovascular disease prescribed all 3 groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter 2 [SGLT2] inhibitors and/or glucagon-like peptide 1 receptor agonists [GLP-1RAs]). DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized clinical trial with 43 US cardiology clinics recruiting participants from July 2019 through May 2022 and follow-up through December 2022. The participants were adults with type 2 diabetes and atherosclerotic cardiovascular disease not already taking all 3 groups of evidence-based therapies. INTERVENTIONS: Assessing local barriers, developing care pathways, coordinating care, educating clinicians, reporting data back to the clinics, and providing tools for participants (n = 459) vs usual care per practice guidelines (n = 590). MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment. The secondary outcomes included changes in atherosclerotic cardiovascular disease risk factors and a composite outcome of all-cause death or hospitalization for myocardial infarction, stroke, decompensated heart failure, or urgent revascularization (the trial was not powered to show these differences). RESULTS: Of 1049 participants enrolled (459 at 20 intervention clinics and 590 at 23 usual care clinics), the median age was 70 years and there were 338 women (32.2%), 173 Black participants (16.5%), and 90 Hispanic participants (8.6%). At the last follow-up visit (12 months for 97.3% of participants), those in the intervention group were more likely to be prescribed all 3 therapies (173/457 [37.9%]) vs the usual care group (85/588 [14.5%]), which is a difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001) and were more likely to be prescribed each of the 3 therapies (change from baseline in high-intensity statins from 66.5% to 70.7% for intervention vs from 58.2% to 56.8% for usual care [adjusted OR, 1.73; 95% CI, 1.06-2.83]; ACEIs or ARBs: from 75.1% to 81.4% for intervention vs from 69.6% to 68.4% for usual care [adjusted OR, 1.82; 95% CI, 1.14-2.91]; SGLT2 inhibitors and/or GLP-1RAs: from 12.3% to 60.4% for intervention vs from 14.5% to 35.5% for usual care [adjusted OR, 3.11; 95% CI, 2.08-4.64]). The intervention was not associated with changes in atherosclerotic cardiovascular disease risk factors. The composite secondary outcome occurred in 23 of 457 participants (5%) in the intervention group vs 40 of 588 participants (6.8%) in the usual care group (adjusted hazard ratio, 0.79 [95% CI, 0.46 to 1.33]). CONCLUSIONS AND RELEVANCE: A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03936660.
引用
- Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 36877177. doi:10.1001/jama.2023.2854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。